William Michael Rosellini
Gründer bei Cytoimmune Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| José Eduardo Vidal | M | - |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 Jahre |
| Richard T. Santulli | M | - |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | - |
| Michael A. Caligiuri | M | 68 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 5 Jahre |
| Michael Neitzel | M | 44 | 7 Jahre | |
| Kent J. George | M | 63 | 7 Jahre | |
| Douglas Williams | M | 66 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 Jahre |
| Jim Crawford | M | 49 | 11 Jahre | |
| Graeme Bell | M | 57 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 1 Jahre |
| Daniel P. Powell | M | 48 | 7 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John Stetson | M | 38 | 3 Jahre | |
| Mark C. Bates | M | - | 12 Jahre | |
| Ronald Conquest | M | 77 |
Rosellini Scientific LLC
 Rosellini Scientific LLC Medical SpecialtiesHealth Technology Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini. | 3 Jahre |
| Miro Zecevic | M | 61 | 1 Jahre | |
| Richard Chernicoff | M | 59 | 2 Jahre | |
| Christina Coughlin | M | 54 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 2 Jahre |
| Craig Allen Nard | M | 57 | 1 Jahre | |
| Stuart Smith | M | 62 | 3 Jahre | |
| Robert Wesley Dittmer | M | 60 | 1 Jahre | |
| Elizabeth Rosellini | M | - |
Rosellini Scientific LLC
Rosellini Scientific LLC Medical SpecialtiesHealth Technology Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini. | 4 Jahre |
| Edward Kovalik | M | 49 | 4 Jahre | |
| Francis Knuettel | M | 58 | 4 Jahre | |
| Dirk Tyler | M | 66 | 2 Jahre | |
| Marissa Welner | F | - |
Maurice A. Deane School of Law at Hofstra University
| 3 Jahre |
| Daniel Wainstein, | - | - |
Maurice A. Deane School of Law at Hofstra University
| 3 Jahre |
| Violin W | M | - |
The University of Texas at Dallas
| 2 Jahre |
| Daniel Wainstein | M | - |
Maurice A. Deane School of Law at Hofstra University
| 3 Jahre |
| Lei Ding | M | 33 |
The University of Texas at Dallas
| 1 Jahre |
| Jamie Barber | M | 47 |
Maurice A. Deane School of Law at Hofstra University
| 3 Jahre |
| Kuan-Yu Liu | M | - | 1 Jahre | |
| Bigvand Hirbod | M | - |
The University of Texas at Dallas
| 4 Jahre |
| David S. Rector | M | 76 | 1 Jahre | |
| Brian Blischak | M | 58 | 2 Jahre | |
| Enrique Sanchez | M | 47 | 2 Jahre | |
| Umesh G. Jani | M | 49 | - | |
| Richard A. Raisig | M | 76 | 1 Jahre | |
| Joshua Bleak | M | 43 | 1 Jahre | |
| Jeffrey Ronaldi | M | 58 |
Lexington Technology Group, Inc.
| 4 Jahre |
| Nathaniel Bradley | M | 48 | - | |
| Erich Spangenberg | M | 63 | 1 Jahre | |
| Daniel Matthew Gelbtuch | M | - | 1 Jahre | |
| Yue Hu | F | - |
The University of Texas at Dallas
| 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 37 | 90,24% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- William Michael Rosellini
- Persönliches Netzwerk
